Patent · US Active

Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use

US11878001B2 · kind B2 · utility

1Cited by

23References

13Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Ricardo Carl Elciario Dolmetsch · Concord, US
Fabrizio Gasparini · Lausen, CH
Baltazar Gomez-Mancilla · Basel, CH
Donald Johns · Cambridge, US

Key dates

Filing date	Jul 30, 2018
Grant date	Jan 23, 2024
Priority date	—
Expiry date	Jul 30, 2038

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/36
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the use of mavoglurant, or a pharmaceutically acceptable salt thereof: in the reduction of cocaine use by a cocaine use disorder patient; in preventing relapse into cocaine use by a cocaine use disorder patient; in the promotion of cocaine abstinence by a cocaine use disorder patient; in in the treatment of the symptoms of depression or anxiety associated with cocaine use disorder.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.